Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar

alvotech-resolves-global-patent-disputes-with-regeneron-and-bayer-over-eylea-biosimilar

Asian people doing medical research in the laboratory

STAP

Alvotech (ALVO) has reached a licensing and settlement agreement with Regeneron (REGN) and Bayer (BAYZF), resolving all remaining patent disputes worldwide related to Alvotech’s biosimilar to Eylea 2 mg, which is approved for marketing in the European Economic Area, United Kingdom and Japan.

In